New biomarker helps determine the optimal treatment for colon cancer

FHS
July 27, 2024
4:55 am

Many people with stage II or III colon cancer receive additional, or adjuvant, chemotherapy following surgery. However, clinical trials have shown that this treatment doesn’t improve the chances of survival for every patient. A study published July 25th, 2024 in Cell Reports Medicine identifies and validates a 10-gene biomarker that potentially predicts whether a stage II or III colon cancer patient will benefit from adjuvant chemotherapy.

BridgeBio eyes US filing for ATTR-CM drug after new PhIII data show ‘fastest’ clinical benefit to date

BridgeBio is preparing to submit an FDA filing for its transthyretin amyloid cardiomyopathy (ATTR-CM) drug candidate, dubbed acoramidis, before the end of the year after

November 14, 2023

Awakn Life Sciences Completes Sale of Awakn Clinics In Norway

As part of its business restructuring process and following its London clinics business sale, UK-based biotech Awakn Life Sciences Corp. AWKNF has sold its Norwegian clinics businesses in a management buyout transaction. Awakn will

August 2, 2023

One year later: The upsides and downsides of the Inflation Reduction Act

Wednesday is the one-year anniversary of President Joe Biden signing the Inflation Reduction Act into law, opening the door to the first government negotiations of

August 17, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.